Immunotherapy

In this interim analysis, PFS rates were compared in PD-L1–defined biomarker subsets of patients receiving maintenance durvalumab or capecitabine.

Immunotherapy, Chemotherapy Combination Improves Survival in Advanced Esophageal Cancer

By

Mark L. Fuerst

June 6, 2021

Researchers have identified a potentially new first-line treatment option for patients with advanced or metastatic esophageal squamous cell carcinoma.

Increased travel burden is associated with a decreased likelihood of receiving adjuvant chemotherapy

Chronic Lymphocytic Leukemia

Upfront Low-Dose Chemo-Immunotherapy Safe, Effective for Elderly With CLL

By

Christina Bennett, MS

April 7, 2021

A study was conducted to assess the safety and efficacy of fludarabine and cyclophosphamide combined with rituximab for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma in elderly patients and those with comorbid conditions.

A doctor checks on a patient.

General Oncology

Preexisting Autoimmune Disease Increases Incidence of irAEs With PD-1 Immunotherapy for Advanced Cancer

By

Katie Kosko

March 1, 2021

Study findings demonstrate the rates of immune-related adverse events and flares of the underlying disorders in this patient population.

A colon affected by ulcerative colitis.

General Oncology

Chronic Immune-Mediated Diarrhea and Colitis Associated With Prolonged Survival in Patients Treated With ICIs

By

Susan Moench, PhD, PA-C

January 5, 2021

The immune-related AE, immune-mediated diarrhea and colitis, can have a limited course or may exist for long-term periods.

Immunotherapy may be effective for some patients with NSCLC as a second-line treatment, but it’s unc

General Oncology

Current State of Combination Therapy for Checkpoint Inhibitors

By

Patricia Chaney

December 22, 2020

Despite the clinical success of combination therapy with immune checkpoint inhibitors many research questions still remain.

Hematologic Cancers

Postmarketing Observational Study of Tisagenlecleucel for ALL or NHL Yields Promising Results

By

Susan Moench, PhD, PA-C

November 24, 2020

Researchers report on results with CAR-T therapy in real-world populations of patients with ALL or NHL.

Researchers are making progress in the search for biomarkers that can help identify which patients a

General Oncology

Biomarkers Aren’t Consistently Used to Select Participants for Immunotherapy Trials

By

Christina Bennett, MS

November 19, 2020

Only a minority of clinical trials evaluating immunotherapeutic agents in 2019 used a biomarker to select patients for enrollment, a study found.

Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.

General Oncology

Targeted Therapies, Immunotherapies, Immunomodulators: A Quick Guide to Cancer Therapy Descriptions

By

Katarina Zimmer, MSci, MS

November 12, 2020

Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.

RCC vaccines are predominantly being developed using autologous tumor cells, dendritic cells, genetically modified tumor cells, and peptides.

Renal Cell Carcinoma

Phase 1 RCC Vaccine Is Safe, But Lacks Clinical Response

By

C. Andrew Kistler, MD, PharmD

November 9, 2020

RCC vaccines are predominantly being developed using autologous tumor cells, dendritic cells, genetically modified tumor cells, and peptides.

Perioperative Blood Transfusions Hike RCC Patient Mortality

Modified Nivolumab-Ipilimumab Dosing Shows No Benefit in Advanced RCC

By

Andrea S. Blevins Primeau, PhD, MBA

November 7, 2020

A modified dosing regimen of nivolumab-ipilimumab for patients with advanced RCC did not provide additional benefit compared with standard dosing.

Next post in IKCS 2020

Angiotensin System Inhibitors Improve OS in mRCC

Phase 3 Trial of Nivolumab With or Without Ipilimumab for Localized RCC After Nephrectomy